Pharmacology of peptic ulcer disease:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Berlin u.a.
Springer
1991
|
| Schriftenreihe: | Handbook of experimental pharmacology
99 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Literaturangaben |
| Beschreibung: | XXII, 464 S. Ill., graph. Darst. |
| ISBN: | 3540528407 0387528407 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV004540342 | ||
| 003 | DE-604 | ||
| 005 | 19911115 | ||
| 007 | t | ||
| 008 | 910812s1991 ad|| |||| 00||| eng d | ||
| 020 | |a 3540528407 |9 3-540-52840-7 | ||
| 020 | |a 0387528407 |9 0-387-52840-7 | ||
| 035 | |a (OCoLC)23177501 | ||
| 035 | |a (DE-599)BVBBV004540342 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-12 |a DE-355 |a DE-20 |a DE-11 |a DE-188 |a DE-578 | ||
| 050 | 0 | |a QP905 | |
| 050 | 0 | |a RC821 | |
| 082 | 0 | |a 616.343061 | |
| 082 | 0 | |a 615/.1 |2 20 | |
| 082 | 0 | |a 616.3/43061 |2 20 | |
| 082 | 0 | |a 615.1 | |
| 084 | |a XI 1701 |0 (DE-625)152977:12907 |2 rvk | ||
| 084 | |a MED 430f |2 stub | ||
| 084 | |a QV 4 |2 nlm | ||
| 084 | |a MED 970f |2 stub | ||
| 245 | 1 | 0 | |a Pharmacology of peptic ulcer disease |c contributors S. B. Benjamin ... Ed. Martin J. Collen and Stanley B. Benjamin |
| 264 | 1 | |a Berlin u.a. |b Springer |c 1991 | |
| 300 | |a XXII, 464 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Handbook of experimental pharmacology |v 99 | |
| 500 | |a Literaturangaben | ||
| 650 | 7 | |a Peptic Ulcer |2 cabt | |
| 650 | 7 | |a Drug Therapy |2 cabt | |
| 650 | 7 | |a Diagnose |2 gtt | |
| 650 | 7 | |a Farmacotherapie |2 gtt | |
| 650 | 7 | |a Pathologische fysiologie |2 gtt | |
| 650 | 7 | |a Ulcus pepticum |2 gtt | |
| 650 | 4 | |a Ulcère peptique - Chimiothérapie | |
| 650 | 4 | |a Ulcère peptique - Physiopathologie | |
| 650 | 4 | |a Peptic Ulcer | |
| 650 | 4 | |a Peptic Ulcer |x drug therapy | |
| 650 | 4 | |a Peptic ulcer |x Chemotherapy | |
| 650 | 4 | |a Peptic ulcer |x Pathophysiology | |
| 650 | 0 | 7 | |a Pharmakologie |0 (DE-588)4045687-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Peptisches Geschwür |0 (DE-588)4075978-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Gastroduodenalulcus |0 (DE-588)4197466-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Geschwür |0 (DE-588)4157049-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pathophysiologie |0 (DE-588)4044898-8 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Peptisches Geschwür |0 (DE-588)4075978-7 |D s |
| 689 | 0 | 1 | |a Pharmakologie |0 (DE-588)4045687-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Gastroduodenalulcus |0 (DE-588)4197466-9 |D s |
| 689 | 1 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Gastroduodenalulcus |0 (DE-588)4197466-9 |D s |
| 689 | 2 | 1 | |a Pathophysiologie |0 (DE-588)4044898-8 |D s |
| 689 | 2 | |5 DE-604 | |
| 689 | 3 | 0 | |a Geschwür |0 (DE-588)4157049-2 |D s |
| 689 | 3 | 1 | |a Pharmakologie |0 (DE-588)4045687-0 |D s |
| 689 | 3 | |5 DE-604 | |
| 700 | 1 | |a Collen, Martin J. |e Sonstige |4 oth | |
| 700 | 1 | |a Benjamin, Stanley B. |e Sonstige |4 oth | |
| 830 | 0 | |a Handbook of experimental pharmacology |v 99 |w (DE-604)BV002390716 |9 99 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002795263&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-002795263 | ||
Datensatz im Suchindex
| _version_ | 1804118674803523584 |
|---|---|
| adam_text | PHARMACOLOGY OF PEPTIC ULCER DISEASE CONTRIBUTORS S.B. BENJAMIN, G.M.A.
BORSCH, S.H. CALDWELL, E.L. CATTAIL M.J. COLLEN, J. DOPPMAN, D.E.
FLEISCHER, J.D. GARDNER D.Y. GRAHAM, A. GUGLIETTA, D. HOLLANDER, C.W.
HOWDEN R.H. HUNT, R.T. JENSEN, D.A. JOHNSON, J.H. LEWIS, P.N. MATON R.W.
MCCALLUM, L.S. MILLER, R.V. NARDI, I.PARIKH J.W. RADEMAKER, A.M. ROSEN,
G. SACHS, A. TARNAWSKI J. VAN DAM, B. WALLMARK, M.M. WOLFE, P.N. YAKSHE
EDITORS MARTIN J. COLLEN AND STANLEY B. BENJAMIN F SPRINGER-VERLAG
BERLIN HEIDELBERG NEW YORK LONDON PARIS TOKYO HONG KONG BARCELONA
BUDAPEST CONTENTS CHAPTER 1 PHARMACOLOGY OF THE PARIETAL CELL G. SACHS,
P.N. MATON, AND B. WALLMARK. WITH 14 FIGURES 1 A. INTRODUCTION 1 B.
ANATOMY OF GASTRIC MUCOSA * * * 1 C. SECRETION BY THE STOMACH 3 I.
GENERAL 3 II. SECRETION AND ABSORPTION BY SURFACE EPITHELIAL CELLS 5 D.
GASTRIC BARRIER 5 E. AGENTS THOUGHT TO AFFECT GASTRIC BARRIER FUNCTION 9
I. SUCRALFATE 9 II. PROSTAGLANDINS 9 III. BISMUTH COMPOUNDS 10 F. ION
TRANSPORT BY THE PARIETAL CELL 10 I. APICAL SURFACE 10 II. BASAL LATERAL
SURFACE . . 12 III. STIMULATION OF ACID SECRETION 12 IV. MECHANISM OF
PARIETAL CELL STIMULATION 13 G. RECEPTOR ANTAGONISTS 15 I. MUSCARINIC
ANTAGONISTS 15 II. H 2 ANTAGONISTS 15 H. MECHANISM OF GASTRIC PROTON
PUMP 16 I. TRANSPORT BY ATPASE 16 II. REACTION CYCLE 17 III. STRUCTURE
OF GASTRIC H + ,K + -ATPASE 19 J. INHIBITORS OF H + ,K + -ATPASE 20 I.
OMEPRAZOLE 21 1. EFFECTS ON ACID SECRETION 21 2. DURATION OF ACTION 22
3. MECHANISM OF ACTION 22 II. REVERSIBLE H + ,K + -ATPASE INHIBITORS 27
III. CLINICAL USE OF PUMP INHIBITORS 30 REFERENCES 31 XII CONTENTS
CHAPTER 2 EPIDERMAL GROWTH FACTOR R.V. NARDI, A. GUGLIETTA, AND I.
PARIKH, WITH 6 FIGURES 37 A. INTRODUCTION 37 B. PERSPECTIVE ON GROWTH
FACTORS 37 C. PERSPECTIVE ON MUCOSAL DISEASE 38 D. EGF STRUCTURE 41 E.
STRUCTURE-ACTIVITY RELATIONSHIPS 41 F. BIOLOGICAL EFFECTS 42 G.
GASTROINTESTINAL ACTIVITY 45 I. DEVELOPMENTAL EFFECTS OF EGF 45 II.
GASTRIC ACID SECRETION 46 III. TROPHIC EFFECTS 47 H. CONCLUSION 48
REFERENCES 50 CHAPTER 3 GASTRIN AND OTHER PEPTIDE HORMONES J. VAN DAM
AND M.M. WOLFE. WITH 6 FIGURES 55 A. INTRODUCTION 55 B. THE MOLECULAR
HETEROGENEITY OF GASTRIN 55 C. GASTRIN RELEASE 57 D. AUTONOMIC CONTROL
OF GASTRIN RELEASE 60 E. BOMBESIN-LIKE PEPTIDES 62 F. SOMATOSTATIN 64 G.
MECHANISM OF GASTRIN-INDUCED GASTRIC ACID SECRETION 69 H. GASTRIN AND
PEPTIC ULCER DISEASE 72 J. HYPERGASTRINEMIC SYNDROMES 74 K. CONCLUSION
77 REFERENCES 77 CHAPTER 4 THE ROLE OF ESSENTIAL FATTY ACIDS IN GASTRIC
AND DUODENAL PROTECTION AND ULCER THERAPY D. HOLLANDER AND A. TARNAWSKI.
WITH 2 FIGURES 89 A. CYTOPROTECTION AND PROSTAGLANDINS 89 I. DEFINITION
OF CYTOPROTECTION 89 II. MUCOSAL SITES OF CYTOPROTECTION 89 1.
PROTECTION OF THE MUCOSAL MICROVASCULATURE 90 2. DIRECT PROTECTION OF
GASTRIC MUCOSAL CELLS 90 III. METABOLISM OF NATURAL AND SYNTHETIC
PROSTAGLANDINS 90 CONTENTS XIII B. ARACHIDONIC ACID CASCADE AND
PROSTAGLANDIN SYNTHESIS BY GASTRIC AND DUODENAL MUCOSA 92 I. ARACHIDONIC
ACID CASCADE 92 II. SOURCES OF ARACHIDONIC ACID FROM MUCOSAL POOLS 92
III. CONTROL OF MUCOSAL PROSTAGLANDIN SYNTHESIS 92 C. DIETARY SOURCES OF
ARACHIDONIC AND LINOLEIC ACIDS 93 I. FOOD SOURCES 93 II. ABSORPTION OF
DIETARY ESSENTIAL FATTY ACIDS 93 III. DISTRIBUTION OF ABSORBED ESSENTIAL
FATTY ACIDS BETWEEN ORGANS 94 IV. THE REQUIREMENT FOR DETERGENTS FOR THE
INTESTINAL OR GASTRIC ABSORPTION OF ESSENTIAL FATTY ACIDS 94 D. GASTRIC
MUCOSAL SYNTHESIS OF ENDOGENOUS PROSTANOIDS FROM DIETARY ESSENTIAL FATTY
ACIDS 95 I. THE REQUIREMENT FOR DETERGENTS FOR ABSORPTION OF DIETARY
ESSENTIAL FATTY ACIDS INTO THE GASTRIC MUCOSA * * 95 II. THE REQUIREMENT
FOR DIRECT GASTRIC MUCOSAL CONTACT WITH SOLUBILIZED ESSENTIAL FATTY
ACIDS FOR MUCOSAL PROTECTION . . . 95 III. GENERATION OF PROSTANOIDS BY
THE GASTRIC MUCOSA FROM SOLUBILIZED ESSENTIAL FATTY ACIDS 96 E. GASTRIC
MUCOSAL PROTECTION BY SOLUBILIZED ESSENTIAL FATTY ACIDS 96 I. ANGIOGENIC
EFFECT OF ESSENTIAL FATTY ACIDS 98 F. DIETARY INTAKE OF ESSENTIAL FATTY
ACIDS 98 I. ANIMAL STUDIES 98 II. HUMAN INTAKE OF DIETARY ESSENTIAL
FATTY ACIDS AND ITS RELATIONSHIP TO PEPTIC ULCER DISEASE . 99 G.
POTENTIAL THERAPEUTIC ADVANTAGES OF DIETARY ESSENTIAL FATTY ACIDS OVER
THE SYNTHETIC PROSTAGLANDINS 101 I. EFFECT OF SHORT-TERM TREATMENT WITH
DIETARY ESSENTIAL FATTY ACIDS ON THE HUMAN GASTRIC MUCOSA * . . . 102 H.
SUMMARY AND CONCLUSION 103 REFERENCES 103 CHAPTER 5 HELICOBACTER PYLORI
G.M.A. BORSCH AND D.Y.GRAHAM. WITH 1 FIGURE 107 A. INTRODUCTION 107 B.
CLINICAL RELEVANCE OF HELICOBACTER PYLORI 107 I. FREQUENCY IN THE
GENERAL POPULATION AND ASSOCIATION WITH CHRONIC GASTRITIS AND PEPTIC
ULCER DISEASE 107 II. CAUSATION 109 1. CHRONIC GASTRITIS 109 2. PEPTIC
ULCER DISEASE 110 XIV CONTENTS C. ATTEMPTS TO ERADICATE HELICOBACTER
PYLORI 112 I. NATURAL HISTORY 113 II. ERADICATION OF HELICOBACTER PYLORI
INFECTIONS 113 III. METHODS TO CONFIRM ERADICATION OF HELICOBACTER
PYLORI INFECTIONS 114 IV. BISMUTH SALTS 115 V. ANTIMICROBIALS AS
MONOTHERAPY 118 VI. DRUG COMBINATIONS 121 1. TRIPLE DRUG COMBINATIONS
121 2. DOUBLE DRUG COMBINATIONS 123 VII. TOXICITY OF ANTIMICROBIALS AND
BISMUTH SALTS 126 VIII. EXPERIMENTAL THERAPEUTIC APPROACHES 128 D.
ERADICATION OI HELICOBACTER PYLORI AND PEPTIC ULCER DISEASE . . . . 130
I. EFFECT ON GASTRITIS 130 II. EFFECT ON HEALING OF DUODENAL ULCERS 130
III. EFFECT ON RELAPSE RATES OF DUODENAL ULCERS . . . . . . . . 132 IV.
EFFECT ON RELAPSE RATES OF GASTRIC ULCERS 135 E. WHOM TO TREAT AND WHAT
TO EXPECT? 135 F. SUMMARY AND CONCLUSIONS 136 REFERENCES 138 CHAPTER 6
DEVELOPMENT OF A NEW GASTRIC ANTISECRETORY DRUG FOR CLINICAL USE C.W.
HOWDEN AND R.H. HUNT 149 A. GENERAL CONSIDERATIONS 149 B. ETIOLOGY AND
PATHOPHYSIOLOGY OF PEPTIC ULCER 149 C. SCOPE FOR PHARMACOLOGICAL
INTERVENTION 151 D. CLINICAL DEVELOPMENT OF A NEW ANTISECRETORY DRUG FOR
PEPTIC ULCER 151 I. PHASE I : 151 II. PHASE II 151 III. PHASE III 156
IV. PHASE IV 157 REFERENCES 157 CHAPTER 7 THERAPEUTIC USE OF OMEPRAZOLE
IN MAN: PHARMACOLOGY, EFFICACY, TOXICITY, AND COMPARISON WITH H 2
RECEPTOR ANTAGONISTS P.N. MATON,G. SACHS, AND B. WALLMARK. WITH 4
FIGURES 159 A. INTRODUCTION 159 B. PHARMACOLOGY 159 CONTENTS XV I.
GENERAL 159 II. PLASMA CONCENTRATIONS 160 III. INHIBITION OF ACID
SECRETION . 161 IV. OTHER ACTIONS OF OMEPRAZOLE 162 1. EFFECT ON
SECRETION OF INTRINSIC FACTOR AND VITAMIN B 12 ABSORPTION 162 2. EFFECT
ON PEPSIN 162 3. EFFECTS ON MOTILITY 163 4. EFFECTS ON GASTRIC ENDOCRINE
FUNCTION 163 C. THERAPEUTIC TRIALS IN ACID-PEPTIC DISEASES 164 I.
OVERVIEW 164 II. DUODENAL ULCER 165 1. EFFECT OF DIFFERENT DOSES OF
OMEPRAZOLE 165 2. COMPARATIVE STUDIES OF OMEPRAZOLE AND H 2 RECEPTOR
ANTAGONISTS 167 3. RELAPSE AFTER STOPPING OMEPRAZOLE THERAPY . . . . . .
169 4. OMEPRAZOLE TREATMENT FOR ULCERS RESISTANT TO H 2 RECEPTOR
ANTAGONISTS 170 III. GASTRIC ULCER 171 1. NONCOMPARATIVE STUDIES OF
OMEPRAZOLE 171 2. COMPARATIVE STUDIES OF OMEPRAZOLE AND RANITIDINE . . .
. 172 3. RELAPSE AFTER STOPPING OMEPRAZOLE THERAPY . . . . . . 173 4.
OMEPRAZOLE TREATMENT FOR ULCERS RESISTANT TO H 2 RECEPTOR ANTAGONISTS
173 IV. REFLUX ESOPHAGITIS 174 1. EFFECT OF DIFFERENT DOSES OF
OMEPRAZOLE 174 2. COMPARATIVE STUDIES OF OMEPRAZOLE AND H 2 RECEPTOR
ANTAGONISTS 175 3. RELAPSE AFTER STOPPING OMEPRAZOLE THERAPY 176 4.
OMEPRAZOLE TREATMENT FOR REFLUX ESOPHAGITIS RESISTANT TO H 2 RECEPTOR
ANTAGONISTS . . 176 V. ZOLLINGER-ELLISON SYNDROME 177 VI. SIDE-EFFECTS
AND TOXICITY 180 D. PROBABLE ROLE OF OMEPRAZOLE IN ACID-PEPTIC DISEASES
181 REFERENCES 181 CHAPTER 8 HYPOTHESIS OF PEPTIC ULCER: A MODERN
CLASSIFICATION OF A MULTIFACTORIAL DISEASE S.H. CALDWELL AND R.W.
MCCALLUM. WITH 3 FIGURES 189 A. INTRODUCTION 189 B. HISTOPATHOLOGY OF
PEPTIC ULCER 190 I. ULCER HISTOLOGY 190 XVI CONTENTS II. GASTRITIS -
DEFINITIONS 191 1. ENDOSCOPIC GASTRITIS 191 2. HISTOLOGIC GASTRITIS 191
C. SCHWARZ S BALANCE 192 I. MUCOSAL DEFENSES 193 1. MEASUREMENT OF THE
BARRIER 193 2. THE MUCUS GEL AND PH GRADIENT 193 3. MUCOSAL HEALING 194
4. MUCOSAL BLOODFLOW 194 5. OTHER MECHANISMS OF DEFENSE 195 II.
AGGRESSIVE FACTORS 195 1. HYDROGEN ION 195 2. ASPARTIC PROTEINASES 196
3. BILE ACIDS 197 4. OXYGEN FREE RADICALS 198 III. RISK FACTORS AS
MODIFIERS OF MUCOSAL DEFENSE 198 1. BLOOD GROUPS 198 2. TOBACCO USE 198
IV. REGULATION OF MUCOSAL DEFENSES: PROSTAGLANDINS AND EPIDERMAL GROWTH
FACTOR 199 1. ROLE OF PROSTAGLANDINS IN MUCOSAL DEFENSE 199 2. EPIDERMAL
GROWTH FACTOR AND OTHER FACTORS 200 D. CLASSIFICATION OF PEPTIC ULCER
DISEASE 201 E. DRUG-INDUCED ULCER DISEASE 202 I. NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS AND ASPIRIN 202 1. MECHANISMS OF NSAID-INDUCED
INJURY 203 2. LESIONS ASSOCIATED WITH NSAID INGESTION 204 3.
HELICOBACTER PYLORI AND NSAID INGESTION 205 II. DRUG-INDUCED ULCERS -
ALCOHOL 205 1. MECHANISMS OF INJURY 205 2. ETHANOL AD ULCERS 206 III.
DRUG-INDUCED ULCERS - STEROIDS 206 1. CORTICOSTEROIDS AND ULCERS 206 2.
EFFECTS OF CORTICOSTEROIDS ON THE MUCOSA 207 F. HELICOBACTER PYLORI AND
PEPTIC ULCER 207 1. HELICOBACTER PYLORI 207 2. THE EFFECT OF
HELICOBACTER PYLORI ON THE MUCOSA AND THE HOST RESPONSE 208 3.
HELICOBACTER PYLORI-ASSOCIATED GASTRODUODENAL ULCERS . . 209 G. ULCERS
ASSOCIATED WITH HYPERSECRETORY STATES 213 H. MALIGNANT ULCERS 215 J.
OTHER TYPES OF CHRONIC RELAPSING PEPTIC ULCER 215 K. ACUTE MUCOSAL
STRESS ULCERATION 216 L. SUMMARY 216 REFERENCES 218 CONTENTS XVII
CHAPTER 9 NONULCER DYSPEPSIA D.A. JOHNSON 229 A. INTRODUCTION 229 B.
DEFINITION 229 C. EPIDEMIOLOGY 230 D. CATEGORIES OF NONULCER DYSPEPSIA
231 I. GASTROESOPHAGEAL REFLUX-LIKE DYSPEPSIA 231 II. DYSMOTILITY-LIKE
DYSPEPSIA 231 III. ULCER-LIKE DYSPEPSIA 232 IV. AEROPHAGIA 232 V.
IDIOPATHIC/ESSENTIAL DYSPEPSIA 232 E. PATHOPHYSIOLOGY 232 I. GASTRIC
ACID 232 II. HELICOBACTER PYLORI 234 III. MOTILITY * *. . . 235 IV.
PSYCHOSOCIAL FACTORS 237 V. ENVIRONMENTAL FACTORS 238 F. DIAGNOSTIC
APPROACH 239 G. TREATMENT 242 H. PROGNOSIS 253 J. CONCLUSIONS 254
REFERENCES 254 CHAPTER 10 THE NATURAL HISTORY OF DUODENAL ULCER DISEASE:
HAS IT BEEN ALTERED BY DRUG THERAPY? J.H. LEWIS 263 A. INTRODUCTION 263
B. INCIDENCE OF DUODENAL ULCER - HISTORICAL PERSPECTIVES 263 I. COHORT
PHENOMENA 265 C. RECENT TIME TRENDS IN THE INCIDENCE OF DUODENAL ULCER
266 D. GEOGRAPHIC INFLUENCES . 267 E. RECENT TRENDS IN HOSPITALIZATION
AND SURGERY FOR DUODENAL ULCER 268 F. SEASONAL VARIATIONS IN DUODENAL
ULCER 270 I. SEASONAL VARIATIONS STUDIED ENDOSCOPICALLY 272 G. NATURAL
HISTORY OF DUODENAL ULCER - PRE-H 2 BLOCKER STUDIES . . . 272 I.
SCANDINAVIAN STUDIES 274 II. EUROPEAN STUDIES 276 III. CURE STUDY 277
XVIII CONTENTS H. DUODENAL ULCER DISEASE IN THE H 2 BLOCKER ERA 278 I.
HOW LONG DOES A DUODENAL ULCER STAY HEALED AFTER TREATMENT? 279 J. ROLE
OF HELICOBACTER PYLORI 280 K NATURAL HISTORY OF UNTREATED ULCERS 280 L.
NATURAL HISTORY OF UNHEALED ULCERS 281 M. CAN DRUG THERAPY PREVENT
DUODENAL ULCER RELAPSE? 282 N. OTHER AGENTS FOR SHORT-TERM MAINTENANCE
THERAPY 285 I. ANTACIDS 285 II. ANTICHOLINERGICS 285 III. TRICYCLIC
ANTIDEPRESSANTS 286 IV. SUCRALFATE 286 V. BISMUTH 286 VI. OMEPRAZOLE 287
O. HOW LONG SHOULD MAINTENANCE THERAPY BE CONTINUED? 287 I. ON-DEMAND
VERSUS INTERMITTENT THERAPY 288 P. SUMMARY 289 REFERENCES 290 CHAPTER 11
REFRACTORY DUODENAL ULCER J.W. RADEMAKER AND R.H. HUNT 301 A.
INTRODUCTION 301 I. DEFINITION 301 II. ADEQUATE TREATMENT AND COMPLIANCE
302 III. HYPERSECRETORY DISORDERS AND NONPEPTIC ULCER DISEASE . . . 306
B. FACTORS WHICH AFFECT HEALING AND RECURRENCE 306 I. ACID
HYPERSECRETION 307 1. PARIETAL CELL SENSITIVITY 308 2. TOLERANCE 309 3.
REBOUND HYPERSECRETION 310 4. GASTRIN . . 310 5. CLINICAL SIGNIFICANCE .
311 II. SMOKING . 311 III. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 312 IV.
HELICOBACTER PYLORI . 312 V. ULCER MORPHOLOGY 313 C. OUTCOME OF
REFRACTORY DUODENAL ULCER TREATMENT TRIALS . . . . 313 I. ACID
SUPPRESSION 314 II. MUCOSAL PROTECTIVE AGENTS 315 III. SURGERY 316 D.
MANAGEMENT 316 CONTENTS XIX I. GENERAL ADVICE 317 II. SPECIFIC TREATMENT
317 REFERENCES 318 CHAPTER 12 IDIOPATHIC GASTRIC ACID HYPERSECRETION
M.J. COLLEN. WITH 8 FIGURES 325 A. INTRODUCTION 325 B. METHOD OF DOING
GASTRIC ANALYSIS 327 C. DEFINITION OF IDIOPATHIC GASTRIC ACID
HYPERSECRETION 328 I. STATISTICAL DEFINITION 328 II. FUNCTIONAL
DEFINITION 328 D. DISEASES ASSOCIATED WITH IDIOPATHIC GASTRIC ACID
HYPERSECRETION . 331 I. GASTROESOPHAGEAL REFLUX DISEASE .-?... 332 II.
DUODENAL ULCER DISEASE 332 III. GASTRIC ULCER DISEASE 333 IV. NONULCER
DYSPEPSIA 333 E. COMPARISON OF IDIOPATHIC GASTRIC ACID HYPERSECRETION
AND ZOLLINGER-ELLISON SYNDROME 334 I. CHARACTERISTICS 334 II. BASAL ACID
OUTPUT, MAXIMAL ACID OUTPUT, AND BASAL ACID OUTPUT/MAXIMAL ACID OUTPUT
RATIO 336 F. HELICOBACTER PYLORI ASSOCIATED WITH IDIOPATHIC GASTRIC ACID
HYPERSECRETION 338 G. THERAPY FOR IDIOPATHIC GASTRIC ACID HYPERSECRETION
340 H. OTHER DATA ON IDIOPATHIC GASTRIC ACID HYPERSECRETION 344 I. BASAL
ACID OUTPUT IN CHILDREN 344 II. BASAL ACID OUTPUT IN OTHER DISORDERS 344
J. CONCLUSIONS 345 REFERENCES 346 CHAPTER 13 ZOLLINGER-ELLISON SYNDROME:
ADVANCES IN DIAGNOSIS AND MANAGEMENT L.S. MILLER, J.D. GARDNER, J.
DOPPMAN, AND R.T. JENSEN. WITH 15 FIGURES 349 A. INTRODUCTION 349 B.
PATHOPHYSIOLOGY 349 C. CLINICAL FEATURES 350 XX CONTENTS D. PROVOCATIVE
TESTS 353 E. DIFFERENTIAL DIAGNOSIS OF DISORDERS WITH INCREASED BASAL
ACID OUTPUT AND INCREASED FASTING GASTRIN CONCENTRATION 355 F. MEDICAL
THERAPY 358 I. H 2 RECEPTOR ANTAGONISTS 359 1. GENERAL 359 2. ABSORPTION
AND EXCRETION OF H 2 RECEPTOR ANTAGONISTS . . 361 3. STUDIES IN PATIENTS
WITH ZOLLINGER-ELLISON SYNDROME . . . 361 4. POTENCY 364 5. ONSET OF
ACTION 364 6. DURATION OF ACTION 364 7. FAILURE 366 8. SAFETY 366 9. USE
367 10. USE OF PARENTERAL H 2 RECEPTOR ANTAGONISTS 368 II. OMEPRAZOLE
369 1. GENERAL 369 2. ABSORPTION, METABOLISM, AND EXCRETION 369 3. ONSET
OF ACTION 371 4. DURATION OF ACTION 371 5. POTENCY 372 6. FAILURE 372 7.
USE 372 8. SAFETY 375 III. ANTICHOLINERGIC AGENTS 375 IV. PROSTAGLANDINS
377 V. SOMATOSTATIN OR SMS 201-995 378 VI. GASTRIN RECEPTOR ANTAGONISTS
379 G. SURGICAL THERAPY 379 H. TUMOR LOCALIZATION . . . 382 J. TREATMENT
OF METASTATIC DISEASE 388 REFERENCES 391 CHAPTER 14 THE PATHOPHYSIOLOGY
AND TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE S.B.BENJAMIN. WITH 3
FIGURES 401 A. INTRODUCTION . 401 B. THE NOSOLOGY OF REFLUX 401 C. WHY
DO HUMANS REFLUX? 402 D. VARIABILITY OF TISSUE RESPONSE TO REFLUX 405 E.
SEQUELAE OF GASTROESOPHAGEAL REFLUX 407 F. EXTRAESOPHAGEAL
MANIFESTATIONS OF REFLUX 408 CONTENTS XXI G. TESTING IN GASTROESOPHAGEAL
REFLUX 410 H. TREATMENT OF GASTROESOPHAGEAL REFLUX 411 J. SURGERY IN
GASTROESOPHAGEAL REFLUX 412 K MANAGEMENT IN REAL LIFE 4I3 L. SUMMARY 414
REFERENCES 414 CHAPTER 15 ENDOSCOPY IN THE EVALUATION AND TREATMENT OF
ACID-PEPTIC DISEASE P.N. YAKSHE AND E.L. CATTAU. WITH 7 FIGURES 417 A.
INTRODUCTION 417 B. ACCURACY 417 C. SAFETY . 418 D. UNCOMPLICATED
ACID-PEPTIC DISEASE 418 I. ENDOSCOPY AS THE INITIAL DIAGNOSTIC MODALITY
418 II. ENDOSCOPY FOLLOWING A RADIOLOGIC PROCEDURE 419 1. NEGATIVE UPPER
GASTROINTESTINAL SERIES 419 2. GASTRIC ULCER 419 3. DUODENAL ULCER 420
III. BIOPSY AND CYTOLOGY 420 IV. DISEASE FOLLOW-UP 421 E.
GASTROINTESTINAL BLEEDING FROM ACID-PEPTIC DISEASE 421 I. GUIDELINES FOR
INTERVENTION 421 II. STIGMATA OF BLEEDING 422 III. ENDOSCOPIC HEMOSTASIS
425 1. ELECTROCOAGULATION 425 2. PHOTOCOAGULATION 429 3. HEATER PROBE .
. . 433 4. CHEMICAL INJECTION 434 5. COMPARISON OF HEMOSTATIC MODALITIES
. 437 F. GASTRIC OUTLET OBSTRUCTION 437 G. SUMMARY 438 REFERENCES 439
CHAPTER 16 VIDEOENDOSCOPY AND DIGITAL IMAGING A.M. ROSEN AND D.E.
FLEISCHER 445 A. INTRODUCTION 445 B. CHARGE-COUPLED DEVICES AND
VIDEOENDOSCOPY - HOW THEY WORK . 446 I. BACKGROUND 446 XXII CONTENTS II.
CCD FUNCTION 446 III. IMAGE TRANSFER 447 IV. MICROPROCESSOR FUNCTION 448
V. COLOR 449 1. BACKGROUND 449 2. VIDEOENDOSCOPIC COLOR REPRODUCTION 449
VI. TECHNICAL EVALUATION 450 VII. CLINICAL USE 452 C. PRACTICAL BENEFITS
AND ADVANTAGES OF VIDEOENDOSCOPY 452 I. IMAGE STORAGE, RETRIEVAL, AND
TRANSFER 452 II. TEACHING/OTHER 453 D. SPECIAL APPLICATIONS 454 I.
MEASUREMENT OF LESION SIZE 454 II. REAL-TIME IMAGE ANALYSIS 454 III.
IMAGE MODIFICATION 455 IV. CHROMOSCOPY AND INFRARED IMAGING * * * 455 V.
MUCOSAL HEMODYNAMICS 456 VI. VIDEOENTEROSCOPY 457 E. THE FUTURE 457
REFERENCES 458 SUBJECT INDEX 463
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV004540342 |
| callnumber-first | Q - Science |
| callnumber-label | QP905 |
| callnumber-raw | QP905 RC821 |
| callnumber-search | QP905 RC821 |
| callnumber-sort | QP 3905 |
| callnumber-subject | QP - Physiology |
| classification_rvk | XI 1701 |
| classification_tum | MED 430f MED 970f |
| ctrlnum | (OCoLC)23177501 (DE-599)BVBBV004540342 |
| dewey-full | 616.343061 615/.1 616.3/43061 615.1 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases 615 - Pharmacology and therapeutics |
| dewey-raw | 616.343061 615/.1 616.3/43061 615.1 |
| dewey-search | 616.343061 615/.1 616.3/43061 615.1 |
| dewey-sort | 3616.343061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03034nam a2200805 cb4500</leader><controlfield tag="001">BV004540342</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19911115 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">910812s1991 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3540528407</subfield><subfield code="9">3-540-52840-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0387528407</subfield><subfield code="9">0-387-52840-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)23177501</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV004540342</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-11</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP905</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC821</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.343061</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.1</subfield><subfield code="2">20</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.3/43061</subfield><subfield code="2">20</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.1</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 1701</subfield><subfield code="0">(DE-625)152977:12907</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MED 430f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QV 4</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MED 970f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacology of peptic ulcer disease</subfield><subfield code="c">contributors S. B. Benjamin ... Ed. Martin J. Collen and Stanley B. Benjamin</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin u.a.</subfield><subfield code="b">Springer</subfield><subfield code="c">1991</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXII, 464 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">99</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Peptic Ulcer</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug Therapy</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Diagnose</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Farmacotherapie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pathologische fysiologie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ulcus pepticum</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ulcère peptique - Chimiothérapie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ulcère peptique - Physiopathologie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peptic Ulcer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peptic Ulcer</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peptic ulcer</subfield><subfield code="x">Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peptic ulcer</subfield><subfield code="x">Pathophysiology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Peptisches Geschwür</subfield><subfield code="0">(DE-588)4075978-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gastroduodenalulcus</subfield><subfield code="0">(DE-588)4197466-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Geschwür</subfield><subfield code="0">(DE-588)4157049-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pathophysiologie</subfield><subfield code="0">(DE-588)4044898-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Peptisches Geschwür</subfield><subfield code="0">(DE-588)4075978-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Gastroduodenalulcus</subfield><subfield code="0">(DE-588)4197466-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Gastroduodenalulcus</subfield><subfield code="0">(DE-588)4197466-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Pathophysiologie</subfield><subfield code="0">(DE-588)4044898-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="3" ind2="0"><subfield code="a">Geschwür</subfield><subfield code="0">(DE-588)4157049-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="1"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Collen, Martin J.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Benjamin, Stanley B.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">99</subfield><subfield code="w">(DE-604)BV002390716</subfield><subfield code="9">99</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002795263&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-002795263</subfield></datafield></record></collection> |
| id | DE-604.BV004540342 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T16:14:03Z |
| institution | BVB |
| isbn | 3540528407 0387528407 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-002795263 |
| oclc_num | 23177501 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-12 DE-355 DE-BY-UBR DE-20 DE-11 DE-188 DE-578 |
| owner_facet | DE-19 DE-BY-UBM DE-12 DE-355 DE-BY-UBR DE-20 DE-11 DE-188 DE-578 |
| physical | XXII, 464 S. Ill., graph. Darst. |
| publishDate | 1991 |
| publishDateSearch | 1991 |
| publishDateSort | 1991 |
| publisher | Springer |
| record_format | marc |
| series | Handbook of experimental pharmacology |
| series2 | Handbook of experimental pharmacology |
| spelling | Pharmacology of peptic ulcer disease contributors S. B. Benjamin ... Ed. Martin J. Collen and Stanley B. Benjamin Berlin u.a. Springer 1991 XXII, 464 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Handbook of experimental pharmacology 99 Literaturangaben Peptic Ulcer cabt Drug Therapy cabt Diagnose gtt Farmacotherapie gtt Pathologische fysiologie gtt Ulcus pepticum gtt Ulcère peptique - Chimiothérapie Ulcère peptique - Physiopathologie Peptic Ulcer Peptic Ulcer drug therapy Peptic ulcer Chemotherapy Peptic ulcer Pathophysiology Pharmakologie (DE-588)4045687-0 gnd rswk-swf Peptisches Geschwür (DE-588)4075978-7 gnd rswk-swf Gastroduodenalulcus (DE-588)4197466-9 gnd rswk-swf Geschwür (DE-588)4157049-2 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Pathophysiologie (DE-588)4044898-8 gnd rswk-swf Peptisches Geschwür (DE-588)4075978-7 s Pharmakologie (DE-588)4045687-0 s DE-604 Gastroduodenalulcus (DE-588)4197466-9 s Pharmakotherapie (DE-588)4076066-2 s Pathophysiologie (DE-588)4044898-8 s Geschwür (DE-588)4157049-2 s Collen, Martin J. Sonstige oth Benjamin, Stanley B. Sonstige oth Handbook of experimental pharmacology 99 (DE-604)BV002390716 99 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002795263&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Pharmacology of peptic ulcer disease Handbook of experimental pharmacology Peptic Ulcer cabt Drug Therapy cabt Diagnose gtt Farmacotherapie gtt Pathologische fysiologie gtt Ulcus pepticum gtt Ulcère peptique - Chimiothérapie Ulcère peptique - Physiopathologie Peptic Ulcer Peptic Ulcer drug therapy Peptic ulcer Chemotherapy Peptic ulcer Pathophysiology Pharmakologie (DE-588)4045687-0 gnd Peptisches Geschwür (DE-588)4075978-7 gnd Gastroduodenalulcus (DE-588)4197466-9 gnd Geschwür (DE-588)4157049-2 gnd Pharmakotherapie (DE-588)4076066-2 gnd Pathophysiologie (DE-588)4044898-8 gnd |
| subject_GND | (DE-588)4045687-0 (DE-588)4075978-7 (DE-588)4197466-9 (DE-588)4157049-2 (DE-588)4076066-2 (DE-588)4044898-8 |
| title | Pharmacology of peptic ulcer disease |
| title_auth | Pharmacology of peptic ulcer disease |
| title_exact_search | Pharmacology of peptic ulcer disease |
| title_full | Pharmacology of peptic ulcer disease contributors S. B. Benjamin ... Ed. Martin J. Collen and Stanley B. Benjamin |
| title_fullStr | Pharmacology of peptic ulcer disease contributors S. B. Benjamin ... Ed. Martin J. Collen and Stanley B. Benjamin |
| title_full_unstemmed | Pharmacology of peptic ulcer disease contributors S. B. Benjamin ... Ed. Martin J. Collen and Stanley B. Benjamin |
| title_short | Pharmacology of peptic ulcer disease |
| title_sort | pharmacology of peptic ulcer disease |
| topic | Peptic Ulcer cabt Drug Therapy cabt Diagnose gtt Farmacotherapie gtt Pathologische fysiologie gtt Ulcus pepticum gtt Ulcère peptique - Chimiothérapie Ulcère peptique - Physiopathologie Peptic Ulcer Peptic Ulcer drug therapy Peptic ulcer Chemotherapy Peptic ulcer Pathophysiology Pharmakologie (DE-588)4045687-0 gnd Peptisches Geschwür (DE-588)4075978-7 gnd Gastroduodenalulcus (DE-588)4197466-9 gnd Geschwür (DE-588)4157049-2 gnd Pharmakotherapie (DE-588)4076066-2 gnd Pathophysiologie (DE-588)4044898-8 gnd |
| topic_facet | Peptic Ulcer Drug Therapy Diagnose Farmacotherapie Pathologische fysiologie Ulcus pepticum Ulcère peptique - Chimiothérapie Ulcère peptique - Physiopathologie Peptic Ulcer drug therapy Peptic ulcer Chemotherapy Peptic ulcer Pathophysiology Pharmakologie Peptisches Geschwür Gastroduodenalulcus Geschwür Pharmakotherapie Pathophysiologie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002795263&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV002390716 |
| work_keys_str_mv | AT collenmartinj pharmacologyofpepticulcerdisease AT benjaminstanleyb pharmacologyofpepticulcerdisease |